JP2017514800A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514800A5
JP2017514800A5 JP2016560809A JP2016560809A JP2017514800A5 JP 2017514800 A5 JP2017514800 A5 JP 2017514800A5 JP 2016560809 A JP2016560809 A JP 2016560809A JP 2016560809 A JP2016560809 A JP 2016560809A JP 2017514800 A5 JP2017514800 A5 JP 2017514800A5
Authority
JP
Japan
Prior art keywords
molecule
composition
polypeptide
nucleic acid
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016560809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514800A (ja
JP6728056B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/024400 external-priority patent/WO2015154059A2/en
Publication of JP2017514800A publication Critical patent/JP2017514800A/ja
Publication of JP2017514800A5 publication Critical patent/JP2017514800A5/ja
Application granted granted Critical
Publication of JP6728056B2 publication Critical patent/JP6728056B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016560809A 2014-04-04 2015-04-04 Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること Expired - Fee Related JP6728056B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461975687P 2014-04-04 2014-04-04
US61/975,687 2014-04-04
PCT/US2015/024400 WO2015154059A2 (en) 2014-04-04 2015-04-04 Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020114165A Division JP2020176123A (ja) 2014-04-04 2020-07-01 Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること

Publications (3)

Publication Number Publication Date
JP2017514800A JP2017514800A (ja) 2017-06-08
JP2017514800A5 true JP2017514800A5 (Direct) 2018-05-17
JP6728056B2 JP6728056B2 (ja) 2020-07-22

Family

ID=54241451

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016560809A Expired - Fee Related JP6728056B2 (ja) 2014-04-04 2015-04-04 Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること
JP2020114165A Pending JP2020176123A (ja) 2014-04-04 2020-07-01 Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020114165A Pending JP2020176123A (ja) 2014-04-04 2020-07-01 Ｈｅｒ３標的ナノ粒子によりトラスツズマブ耐性ｈｅｒ２＋乳癌を標的にすること

Country Status (13)

Country Link
US (2) US9850293B2 (Direct)
EP (1) EP3129066B1 (Direct)
JP (2) JP6728056B2 (Direct)
KR (1) KR20160141751A (Direct)
CN (1) CN106170305A (Direct)
AU (1) AU2015240460A1 (Direct)
BR (1) BR112016023025A2 (Direct)
CA (1) CA2943297A1 (Direct)
IL (1) IL248046B (Direct)
MX (1) MX2016013025A (Direct)
RU (1) RU2692104C2 (Direct)
WO (1) WO2015154059A2 (Direct)
ZA (1) ZA201607375B (Direct)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
MX2015015434A (es) * 2013-05-08 2016-03-15 Cedars Sinai Medical Center Corroles dirigidas para toxicidad tumoral y rm.
AU2015206271B2 (en) * 2014-01-17 2020-02-27 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
EP3129066B1 (en) 2014-04-04 2020-08-12 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
US20190175747A1 (en) * 2016-05-27 2019-06-13 Cedars-Sinai Medical Center Drug-delivery nanoparticles and treatments for drug-resistant cancer
CN106474472B (zh) * 2016-10-11 2021-06-08 连云港市第一人民医院 肿瘤曲妥珠单抗靶向anti-miR-21纳米粒子及其制备方法
WO2019136005A1 (en) * 2018-01-02 2019-07-11 Cedars-Sinai Medical Center Nanoparticles for the targeted delivery of therapeutic polypeptides
CN113950337A (zh) * 2019-01-03 2022-01-18 金圣千 利用pH依赖性细胞膜穿透肽的药物载体以及所述药物载体与药物的复合体
KR102182985B1 (ko) * 2019-01-03 2020-11-26 주식회사 바이오이즈 pH 의존적 막 투과성 펩타이드를 이용한 약물 운반체 및 그것과 약물의 복합체
WO2021231528A1 (en) * 2020-05-12 2021-11-18 Rush University Medical Center Compositions and methods for treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US6333396B1 (en) 1998-10-20 2001-12-25 Enzon, Inc. Method for targeted delivery of nucleic acids
CA2391534A1 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
AU2002240201A1 (en) 2001-02-02 2002-08-19 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules
WO2002094318A1 (en) 2001-05-18 2002-11-28 University Of Southern California Vector for targeted delivery to cells
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
JP2004024724A (ja) 2002-06-28 2004-01-29 Biopol Co Ltd 多層構造の微細多孔性フォームドレッシング材及びその製造方法
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
US7205387B2 (en) 2003-08-28 2007-04-17 Agency For Science, Technology And Research Recombinant polypeptide useful for neurotrophin receptor mediated gene delivery and as neurotrophin agonist
TWI355894B (en) 2003-12-19 2012-01-11 Du Pont Herbicidal pyrimidines
WO2005117992A2 (en) 2004-05-30 2005-12-15 Cemines, Inc. Controlled delivery of therapeutic compounds
US8057821B2 (en) 2004-11-03 2011-11-15 Egen, Inc. Biodegradable cross-linked cationic multi-block copolymers for gene delivery and methods of making thereof
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007137117A2 (en) 2006-05-17 2007-11-29 Massachusetts Institute Of Technology Aptamer-directed drug delivery
US9078927B2 (en) 2007-07-06 2015-07-14 Cedars-Sinai Medical Center Self-assembling complex for targeting chemical agents to cells
WO2009151539A1 (en) 2008-05-24 2009-12-17 Sirnaomics, Inc. COMPOSITIONS AND METHODS USING siRNA MOLECULES FOR TREATMENT OF GLIOMAS
WO2010078517A2 (en) 2008-12-31 2010-07-08 Sirnaomics, Inc. Compositions and methods using sirna molecules and sirna cocktails for the treatment of breast cancer
WO2010085665A2 (en) 2009-01-23 2010-07-29 Cedars-Sinai Medical Center Targeted delivery system
WO2011028850A1 (en) 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
WO2011094335A2 (en) 2010-01-26 2011-08-04 Yale University Microrna signatures predicting responsiveness to anti-her2 therapy
EP2852333B1 (en) 2012-05-22 2021-12-15 Smith & Nephew plc Apparatuses for wound therapy
PL2880160T3 (pl) 2012-08-03 2019-03-29 Cedars-Sinai Medical Center Izolowanie wzmacniających transport mutantów białka dostarczającego lek
MX2015015434A (es) 2013-05-08 2016-03-15 Cedars Sinai Medical Center Corroles dirigidas para toxicidad tumoral y rm.
AU2015206271B2 (en) 2014-01-17 2020-02-27 Cedars-Sinai Medical Center Receptor targeting constructs and uses thereof
EP3129066B1 (en) 2014-04-04 2020-08-12 Cedars-Sinai Medical Center Targeting trastuzumab-resistant her2+breast cancer with a her3-targeting nanoparticle
CA2959492A1 (en) 2014-08-27 2016-03-03 Thomas Primiano Anti-tumor compositions and methods

Similar Documents

Publication Publication Date Title
JP2017514800A5 (Direct)
Araste et al. Peptide-based targeted therapeutics: Focus on cancer treatment
IL292193B2 (en) Anti-b7-h1 antibodies for treating tumors
JP2016535009A5 (Direct)
JP2019527706A5 (Direct)
EP4335511A3 (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
JP2018529656A5 (Direct)
JP2008502584A5 (Direct)
JP2019526578A5 (Direct)
Izar et al. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer
JP2010540453A5 (Direct)
WO2018115231A3 (en) Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
JP2008507536A5 (Direct)
JP2017533920A5 (Direct)
JP2021502980A5 (Direct)
JP2019506862A5 (Direct)
JP2013166763A5 (Direct)
JP6101827B2 (ja) がん幹細胞の増殖抑制剤および細胞内活性酸素蓄積誘導剤
JP2015512398A5 (Direct)
JP2016530233A5 (Direct)
JP2016515628A5 (Direct)
JP2015514756A5 (Direct)
JP2014502955A5 (Direct)
JP2017533223A5 (Direct)
MX2017001012A (es) Metodo para inhibir ras activado intracelular utilizando anticuerpos de tipo inmunoglobina intactos que tienen capacidad penetratoria de citosol y uso del mismo.